Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2011; 17(12): 1622-1630
Published online Mar 28, 2011. doi: 10.3748/wjg.v17.i12.1622
Published online Mar 28, 2011. doi: 10.3748/wjg.v17.i12.1622
Table 1 Summary of laboratory results at initial presentation
Reference range | No. of patients measured | mean ± SD | % of patients outside reference range | |
White cell count (× 109/L) | 4.0-11.0 | 62 | 15.0 ± 6.3 | 74% |
Neutrophil count (× 109/L) | 2.0-8.0 | 62 | 12.9 ± 5..9 | 82% |
Haemoglobin (g/L) | 135-180 | 62 | 118 ± 21 | 24% Hb < 100 g/L |
Platelets (× 109/L) | 150-400 | 320 ± 202 | 42% | |
C-reactive protein (mg/L) | < 5 | 47 | 272 ± 119 | 100% (47/47) |
Urea (mmol/L) | 3.1-8.1 | 62 | 8.2 ± 5.96 | 29% Urea > 8.1 mmol/L |
Creatinine (μmol/L) | 60-100 | 62 | 105 ± 60 | 42% Cr > 100 μmol/L |
16% Cr > 150 μmol/L | ||||
Albumin (g/L) | 35-46 | 62 | 30 ± 7.0 | 73% |
AST (U/L) | 12-36 | 61 | 127 ± 301 | 67% |
ALT (U/L) | 5-40 | 62 | 118 ± 222 | 73% |
ALP (U/L) | 41-119 | 61 | 209 ± 140 | 71% |
GGT (U/L) | 5-65 | 62 | 191 ± 201 | 75% |
Bilirubin (μmol/L) | 3-18 | 61 | 30 ± 39 | 54% Bil > 18 μmol/L 13% Bil > 50 μmol/L |
Glucose (mmol/L) | 3.5-5.5 | 47 | 7.8 ± 2.6 | 15% (7/47) Glucose > 10 mmol/L |
INR | ≤ 1.5 | 53 | 1.3 ± 0.56 | 13% (7/53) |
Table 2 Summary of physical examination findings on presentation
Clinical finding | n (%) |
Fever (T > 37.5) | 33 (59) |
Hypotension (SBP < 100) | 7 (13) |
Tachycardia (HR ≥ 100) | 29 (52) |
Peritonism | |
None | 49 (86) |
Localized guarding | 8 (14) |
Generalized peritonism | 0 (0) |
Location of tenderness | |
Non tender abdomen | 20 (35) |
Right upper quadrant | 22 (39) |
Other abdominal tenderness | 15 (26) |
Table 3 Summary of microbiology results for blood culture results, liver abscess aspirate culture results, and presumed causative pathogen
Organism | n (% of patients with culture results) | ||
Positive blood cultures | Positive liver aspirate cultures | Causative pathogen | |
Streptococcus milleri | 8 (14) | 12 (24) | 16 (25) |
Klebsiella species | 9 (16) | 8 (16) | 13 (21) |
K. pneumoniae | 7 | 8 | 11 |
K. oxytoca | 1 | 0 | 1 |
K. terrigena | 1 | 0 | 1 |
Escherichia coli | 6 (11) | 3 (5.9) | 10 (16) |
Mixed1 | 2 (3.6) | 6 (12) | 5 (8) |
Fusobacterium necrophorum | 1 (1.8) | 1 (2.0) | 2 (3.2) |
Pseudomonas aeruginosa | 0 (0) | 1 (2.0) | 1 (1.6) |
Lactobacillus | 0 (0) | 1 (2.0) | 1 (1.6) |
Corynebacterium urealyticum | 0 (0) | 1 (2.0) | 1 (1.6) |
Citrobacter koseri | 0 (0) | 1 (2.0) | 1 (1.6) |
Staphylococcus aureus2 | 1 (1.8) | 0 (0) | 0 (0) |
Causative organism not identified | - | - | 13 (21) |
Total negative | 29 (52) | 17 (33) | - |
Total positive | 27 (48) | 34 (67) | 50 (79) |
Total number of patients with available culture results | /55 | /51 | /63 |
Table 4 Summary of the presumed aetiology of the patients’ pyogenic liver abscesses
Aetiology | n (%) |
Cryptogenic | 20 (34) |
Biliary | 14 (22) |
Portal (e.g. appendicitis, diverticulitis) | 12 (20) |
Haematogenous (other bacteremic source) | 7 (11) |
Direct (e.g. pericholecystic abscess, RFA) | 6 (9.4) |
Table 5 Summary of interventions
Initial intervention (%) | → | Secondary intervention (%) | → | Further interventions (%) | |||
AB | 5 (7.9) | → | RA | 1/5 (20) | |||
Other | 1/5 (20) | ||||||
RD | 43 (68) | → | RA | 1/43 (2.3) | |||
SG | 5/43 (12) | ||||||
RD | 13/43 (30) | → | SG | 1/13 (7.7) | |||
RD | 3/13 (23) | ||||||
RA | 11 (18) | → | RD | 2/11 (18) | |||
SG | 2/11 (18) | ||||||
SG | 2 (3.2) | - | - | ||||
Other | 2 (3.2) | → | SG | 1/2 (50) |
Table 6 Complications occurring in 21 patients
Complication | n |
Acute renal failure | 7 |
Abdominal collection/sepsis | 4 |
Thoracic empyema/large pleural effusion requiring surgical drainage | 4 |
Multiple organ failure | 2 |
Biliary fistula | 2 |
Hemorrhage from percutaneous drainage | 2 |
Portal vein thrombosis | 1 |
Hepatic vein thrombosis | 1 |
Subcapsular hematoma from percutaneous drainage | 1 |
Myocardial infarction | 1 |
Necrosis of terminal phalanges | 1 |
Table 7 Univariate analysis of factors that may lead to failure in initial percutaneous therapy
Treatment successful | Treatment failure | P-value | |
Demographic characteristics and history | |||
Age (yr), mean (95% CI) | 67 (62-73) | 63 (57-69) | 0.26 |
Sex (M:F) | 20:11 | 15:08 | 1.00 |
Prodrome (days), median (IQR) | 7 (3-20) | 7 (5-14) | 0.88 |
History of gallstone disease, n (%) | 8 (27) | 5 (22) | 0.76 |
History of diabetes mellitus, n (%) | 4 (13) | 3 (13) | 1.00 |
Chronic renal failure, n (%) | 1 (3.3) | 1 (4.4) | 1.00 |
Current cancer, n (%) | 6 (20) | 5 (22) | 1.00 |
Examination findings, n (%) | |||
Fever | 16 (53) | 12 (63) | 0.56 |
Tachycardia | 13 (43) | 11 (58) | 0.39 |
Hypotension | 4 (13) | 1 (5.3) | 0.64 |
Laboratory findings, mean (95% CI) | |||
Leucocytes (× 109/L) | 15.2 (13.1-17.4) | 13.6 (11.2-16.0) | 0.30 |
Neutrophil (× 109/L) | 12.8 (10.8-14.9) | 11.7 (9.5-13.8) | 0.43 |
Haemoglobin (g/L) | 114 (106-121) | 120 (110-130) | 0.26 |
Platelet (× 109/L) | 341 (255-426) | 319 (250-388) | 0.70 |
Urea (mmol/L) | 9.3 (6.8-11.9) | 6.5 (5.3-7.7) | 0.07 |
Creatinine (μmol/L) | 110 (83-138) | 103 (86-121) | 0.70 |
CRP (mg/L) | 287 (236-338) | 258 (193-324) | 0.47 |
Albumin (g/L) | 32 (29-35) | 28 (25-31) | 0.045 |
AST (U/L) | 187 (30-344) | 70 (43-97) | 0.19 |
ALT (U/L) | 149 (37-260) | 84 (55-114) | 0.33 |
GGT (U/L) | 193 (115-271) | 183 (96-269) | 0.85 |
ALP (U/L) | 201 (154-249) | 203 (143-262) | 0.97 |
Bilirubin (μmol/L) | 29 (13-45) | 26 (19-32) | 0.75 |
Glucose (mmol/L) | 7.9 (6.7-9.0) | 7.6 (6.4-8.9) | 0.79 |
INR | 1.2 (1.1-1.3) | 1.4 (1.0-1.8) | 0.24 |
Microbiology | |||
Positive blood culture, n (%) | 12 (43) | 9 (47) | 0.78 |
Positive aspirate culture, n (%) | 17 (61) | 17 (85) | 0.11 |
Organism, n (%) | 0.19 | ||
Streptococcus milleri | 8 (26) | 8 (35) | |
Klebsiella species | 5 (16) | 7 (30) | |
Escherichia coli | 6 (19) | 0 (0) | |
Other | 6 (19) | 4 (17) | |
Negative cultures | 6 (19) | 4 (17) | |
Imaging findings | |||
Multiple abscesses, n (%) | 7 (24) | 10 (45) | 0.14 |
Side of liver, n (%) | 0.10 | ||
Left | 5 (17) | 2 (10) | |
Right | 23 (77) | 13 (62) | |
Bilateral involvement | 2 (7) | 6 (29) | |
Abscess diameter, median (IQR) | 6.0 (3.8-9.5) | 6.5 (5.0-8.4) | 0.83 |
Diameter > 5 cm | 11 (41) | 7 (35) | 1.00 |
Presence of gas, n (%) | 5 (17) | 1 (5) | 0.38 |
Biliary duct dilatation, n (%) | 6 (20) | 2 (10) | 0.45 |
Intervention | |||
Percutaneous drain insertion (vs percutaneous aspiration) | 24 (77) | 19 (83) | 0.74 |
Cause | |||
Presumptive cause, n (%) | 0.60 | ||
Cryptogenic | 8 (29) | 9 (41) | |
Biliary | 7 (25) | 5 (23) | |
Portal | 6 (21) | 4 (18) | |
Haematogenous | 5 (18) | 3 (14) | |
Direct | 2 (7) | 1 (5) |
- Citation: Pang TC, Fung T, Samra J, Hugh TJ, Smith RC. Pyogenic liver abscess: An audit of 10 years’ experience. World J Gastroenterol 2011; 17(12): 1622-1630
- URL: https://www.wjgnet.com/1007-9327/full/v17/i12/1622.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i12.1622